Skip to main content
OpenTrials
Completed

NCT Number: NCT05091710

Haiti Community Health Workers (CHW) Adaptation

Evidence-based interventions to improve linkage and outcomes for heart failure (HF) patients requires input from stakeholders: patients, community health workers (CHWs), healthcare staff, and health system administrators.

In this research the investigators will assess a CHW intervention designed to improve linkage to care for HF patients. This intervention was systematically adapted for use in rural Haiti in a prior study using the Assessment, Decisions, Administration, Production, Topical Experts, Integration, Training staff, Testing (ADAPT-ITT) framework. The ADAPT-ITT framework provides 8 sequential phases to adapt interventions and programs to new target audiences. It has been applied successfully to the adaptation of several interventions for HIV among under-resourced communities leading to randomized clinical trials. With the first 6 steps of the ADAPT-ITT framework completed in a prior study, this protocol outlines the training and testing of the adapted CHW intervention.

In addition to assessing the feasibility, appropriateness, and acceptability of the adapted intervention through participants' feedback, the investigators will assess its efficacy in improving HF outcomes. The proposed intervention is targeted at both the patient domain - through improved peer support - and health system domain - by improving health system navigation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zanmi Lasante/Hôpital Universitaire de Mirebalais

Mirebalais, Haiti

About this study

This is a clinical trial involving the training of 6 CHWs in a linkage-to-care intervention and the testing of the intervention on 30 HF patients. In a prior study, the ADAPT-ITT framework was used to adapt a CHW-based intervention for post-discharge HF patients in Haiti. This study represents the last two phases of the ADAPT-ITT framework: Training and Testing.

The study population will include adult HF patients (> 18 years of age), hospitalized for more than 48 hours, discharged from Hôpital-Universitaire de Mirebalais (HUM), without a prior clinic visit, living in Mirebalais Commune. Patients will be recruited for study participation shortly before discharge. A comparison group of 30 HF patients will be recruited and will not participate in the follow up care intervention. Those patients will be retrospectively identified from the medical record. The comparison group and will not receive any intervention. Six experienced CHWs will be trained to conduct the linkage to care intervention.

The intervention will include study visits in the form of home visits and phone calls performed by CHWs during which they will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for patient participant:

  • Adult HF patients
  • Hospitalized >48 hours at Hôpital-Universitaire de Mirebalais (HUM)
  • Anticipated discharge from HUM within 1-3 days
  • Living in Mirebalais Commune, Haiti Inclusion criteria for historical patient reference group
  • Adult HF patients
  • Hospitalized >48 hours at HUM
  • Discharged from HUM within the 12 months preceding the intervention
  • Living in Mirebalais Commune

Exclusion criteria

for patient participant and historical patient reference group:

  • None

Inclusion criteria

for CHW

  • Adult
  • Provide inpatient or outpatient care to HF patients
  • Working in in Mirebalais

Exclusion criteria

for CHW

  • None

Inclusion criteria

for healthcare staff (provider/administrator)

  • Hospital leadership involved in supervision of clinical care programs (i.e. Chief Executive Officer, Chief Medical Officer, Chief Operations Officer, Chief Nursing Officer, etc.)
  • Leaders of the Community Health Department - including the nurse Director of Community Health, and Community Health Worker Supervisors.
  • Healthcare providers at HUM involved in the care of patients with heart failure (i.e. internal medicine physicians, inpatient hospital nurses, outpatient clinic physicians, outpatient clinic nurses, etc.)

Exclusion criteria

for healthcare staff (provider/administrator)

  • None

Treatment and study plan

HF follow up care

Other

The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.

HF Standard of Care (SOC)

Other

SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.

Primary outcomes

  1. Acceptability of HF follow up program to patients

    Time frame: 90 days

    Acceptability of the HF follow up program to patients will be assessed using a 5-point Likert scale response to the question "Was it acceptable to have a CHW come to your home to educate you in your heart failure care and encourage clinic follow-up?" where 1=not acceptable, 5=very acceptable.

  2. Acceptability of HF follow up program to Community Health Workers (CHWs)

    Time frame: 12 months

    Acceptability of the HF follow up program to CHWs will be assessed using a 5-point Likert scale response to the question "Was it acceptable to have a CHW come to your home to educate you in your heart failure care and encourage clinic follow-up?" where 1=not acceptable, 5=very acceptable.

  3. Acceptability of HF follow up program to nurses/doctors

    Time frame: 12 months

    Acceptability of the HF follow up program to nurses/doctors will be assessed using a 5-point Likert scale response to the question "Was it acceptable to have a CHW come to your home to educate you in your heart failure care and encourage clinic follow-up?" where 1=not acceptable, 5=very acceptable.

  4. Appropriateness of HF follow up program to patients

    Time frame: 90 days

    Appropriateness of HF follow up program to patients will be assessed using a 5-point Likert scale response to the question "Were you satisfied with the CHWs interactions with you?" where 1=not acceptable, 5=very acceptable.

  5. Appropriateness of HF follow up program to CHWs

    Time frame: 12 months

    Appropriateness of HF follow up program to CHWs will be assessed using a 5-point Likert scale response to the question "Were you satisfied with the CHWs interactions with you?" where 1=not acceptable, 5=very acceptable.

  6. Appropriateness of HF follow up program to nurses/doctors

    Time frame: 12 months

    Appropriateness of HF follow up program to nurses/doctors will be assessed using a 5-point Likert scale response to the question "Were you satisfied with the CHWs interactions with you?" where 1=not acceptable, 5=very acceptable.

  7. Feasibility of HF follow up program to patients

    Time frame: 90 days

    Feasibility of HF follow up program to patients will be assessed by the percent of invited eligible patients who consent to participate. The higher the percentage of consenting patients, the more feasible the program.

  8. Feasibility of HF follow up program to CHWs

    Time frame: 90 days

    Feasibility of HF follow up program to CHWs will be assessed by the percent of invited CHWs who complete the training. The higher the percentage, the more feasible the program.

  9. Fidelity of HF follow up program

    Time frame: 90 days

    Fidelity of HF follow up program will be assessed by the percent of home visit checklist items completed by CHWs. The higher the percentage, the greater the fidelity.

  10. HF follow up program intervention components delivered

    Time frame: 90 days

    Assessed by the number of interventions delivered based abstracted from the home visit checklist completed by the CHWs.

  11. Completion of scheduled visits

    Time frame: 90 days

    Assessed by the percent of scheduled visits that were completed from the CHW records.

  12. Percent of visits with all home visit checklist items completed

    Time frame: 90 days

    Assessed by dividing the number of visits with all home visit checklist items completed by the total number of visits.

Secondary outcomes

  1. Linkage of HF patients

    Time frame: 30 days

    Percent of patients that complete 30 day follow up visit

  2. Retention of HF patients

    Time frame: 90 days

    Percent of patients that complete 90 day follow up visit

  3. Hospital readmission rate

    Time frame: 90 days

    Percent of patients that are readmitted to the hospital abstracted from the medical charts

  4. Patient symptoms based on the New York Heart Association (NYHA) Classification

    Time frame: 90 days

    A New York Heart Association (NHYA) class from 1 to 4 will be assigned to each patient. The higher the classification the more serious the symptoms

    NYHA Classification - The Stages of Heart Failure:

    Class 1 - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.

    Class 2 - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.

    Class 3 - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest.

    Class 4 - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

  5. Patient quality of life assessed European Quality of Life 5D (EuroQol 5D)

    Time frame: 30 days, 90 days

    Quality of life of patients will be assessed with the European Quality of Life 5D (EuroQol 5D) level. ThevEuropean Quality (EQ)-5D descriptive system is a preference-based Health-related quality of life (HRQL) measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers given to EQ-5D permit to find 243 unique health states or can be converted into EQ-5D index an utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).

  6. Symptoms and quality of life based on the Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: 30 days, 90 days

    The KCCQ will be used to assess symptoms, physical and social limitations, and quality of life in HF patients. Scores are scaled from 0 to 100 and will be summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.

  7. Mortality rate in HF patients

    Time frame: 90 days

    The number of HF patients who die within 90 days following discharge will be calculated.

Sponsors and collaborators

Lead sponsor

Boston Medical Center

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Pilot Trial of a Community Health Worker Intervention to Improve Heart Failure Care in Rural Haiti

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Oct 25, 2021
Registry last updated
Nov 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.